top of page

Novartis to Strengthen Oncology Pipeline with Agreement to Acquire MorphoSys AG, Including Late-Stage BET Inhibitor Pelabresib for Myelofibrosis (MF)

Myelofibrosis (MF) is a rare blood cancer affecting blood cell production in the bone marrow. The bone marrow fills with fibrous and scar tissue that prevents the normal function of the stem cells. Pelabresib has recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement with a well-tolerated safety profile in Phase 3 MANIFEST-2 study.

Takeda and Protagonist Therapeutics, Inc., today announced the signing of a worldwide license and collaboration agreement for the development and commercialization of rusfertide

Novartis today announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing innovative medicines in oncology. Upon completion of the acquisition, Novartis will own pelabresib , a novel and potentially practice changing treatment option with a well-tolerated safety profile provided in combination with ruxolitinib for patients with MF.

“We are excited about the opportunity of bringing pelabresib, a potential next-generation treatment combined with ruxolitinib, to people living with myelofibrosis, a rare and debilitating form of blood cancer,” said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer of Novartis. “With the planned acquisition of MorphoSys, we aim to further strengthen our leading pipeline and portfolio in oncology, adding to our capabilities and expertise. Building on our long-standing development partnership with MorphoSys, we look forward to continuing our work together to realize the full impact and value of their investigational medicines for patients with unmet needs.”

Check out the official press release to delve into the details!

25 views0 comments


Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page